Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.

K, Kario; K, Okada; M, Kato; M, Nishizawa; T, Yoshida; T, Asano; K, Uchiyama; Y, Niijima; T, Katsuya; H, Urata; JI, Osuga; T, Fujiwara; S, Yamazaki; N, Tomitani; H, Kanegae

doi:10.1161/circulationaha.118.037076

Public

Twenty-Four-Hour Blood Pressure-Lowering Effect of a Sodium-Glucose Cotransporter 2 Inhibitor in Patients With Diabetes and Uncontrolled Nocturnal Hypertension: Results From the Randomized, Placebo-Controlled SACRA Study.

Shared by NobleBlocks on Nov 29, 2018 • 12:00 AM UTC

Authors:

Kario K

Okada K

Kato M

Abstract

<h4>Background</h4>The risk of cardiovascular disease and mortality in salt-sensitive patients with diabetes mellitus and uncontrolled nocturnal hypertension is high. The SACRA (Sodium-Glucose Cotransporter 2 [SGLT2] Inhibitor and Angiotensin Receptor Blocker [ARB] Combination Therapy in Patients Wi...

Subject

Hypertension

Type 2 diabetes mellitus

Natriuretic peptides

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!